Nurix TherapeuticsNRIX.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Nurix Therapeutics (NRIX.O) trades at a P/E of 9.04x, P/B of 2.76x, P/S of 3.80x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E, given a shorter listing history, currently only has industry percentile data, at the 10th percentile; P/B sits at the 45th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 10th percentile within its industry and the 15th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 34.1 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Nurix Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: NRIX · NRIX
Want the full picture on whether Nurix Therapeutics (NRIX.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 9.04 | — | — | — | — | ||
| P/B (MRQ) | 2.76 | ||||||
| P/S (TTM) | 3.80 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |